Vertex reported second-quarter revenue of $203.97 million, a 10.5% increase from the same period last year, and earnings per share of $0.20. The revenue figure exceeded the Zacks Consensus Estimate of $202 million by 0.98%, while EPS beat the consensus of $0.19 by 5.26%. Annual Recurring Revenue reached $703.4 million, slightly above the $699.88 million analyst estimate. Software subscriptions revenue came in at $174.75 million, and services revenue was $29.22 million, both surpassing analyst projections.
VertexQ2 revenue and EPS beat estimates, with ARR and subscription revenue exceeding expectations.
Vertex Pharmaceuticals Inc